Prognostic and Predictive Implications of Cytogenetics and Genomics

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• Chronic lymphocytic leukemia (CLL) exhibits significant genomic heterogeneity.
• TP53 gene aberrations are key genomic drivers impacting treatment decisions and prognosis in CLL.
• Traditional chemo(immuno)therapy outcomes are linked to specific genetic abnormalities.

Purpose of the Study:

• To review the prognostic and predictive value of common genomic abnormalities in CLL.
• To evaluate how novel therapeutic agents impact the significance of these genomic aberrations.
• To discuss the evolving role of genetic markers in CLL treatment selection.

Main Methods:

• Literature review of clinical trials and studies on CLL genomic abnormalities.
• Analysis of prognostic and predictive data associated with genetic aberrations.
• Assessment of the impact of novel agents on established genetic markers' significance.

Main Results:

• Recurrent genetic abnormalities in CLL have historically predicted poor outcomes with conventional therapy.
• Emerging data from trials with novel agents suggest a diminished predictive role for some genomic aberrations, including TP53.
• The established unfavorable impact of genomic aberrations is being questioned in the current treatment landscape.

Conclusions:

• The prognostic and predictive value of genomic abnormalities in CLL is being redefined by novel therapeutic strategies.
• TP53 gene status may have a different implication in the context of novel agents compared to chemo(immuno)therapy.
• Further research is needed to fully elucidate the role of genomic heterogeneity in guiding CLL treatment with modern therapies.